APS
2026 APS Annual Convention · 2026
Who Funds the Trial Matters: Adverse Event Monitoring In Psilocybin Research Is Associated with Reported Funding Sources
Session: Poster Session XII
Authors
- Elliana NathPresenting Author
Emory University - Elliana NathPresenting Author
Bradley Hasbro Children’s Research Center, Brown University Health - Zina Alshekhlee
Emory University - Joy Ren
Dana-Farber Cancer Institute - Anusha Kak
Emory University - Rhea Kapur
Cleveland Clinic - Rose Delony
National Institutes of Health - Billy Wang
University of Pennsylvania - Zainab Salako
Emory University - Gillian Hue
Emory University - Roman Palitsky
Emory University - Louise Hecker
Baylor College of Medicine
Abstract
Funding appears to influence adverse event (AE) reporting in U.S. psilocybin trials (K = 39, 1959-2024). AE and safety reporting were analyzed in association with listed funding sources, revealing trends between industry- versus federally-funded clinical trials of psilocybin. No study used a psychedelic-specific AE scale, highlighting a concerning methodological gap.
